April 1, 2016

Washington, DC

The Association of Reproductive Health Professionals applauds the US Food and Drug Administration's (FDA) recent approval of new labeling information for mifepristone, the medication abortion pill marketed in the US as Mifeprex. We join our colleagues at the American Medical Association, the American College of Obstetricians and Gynecologists, and many other professional and reproductive health and rights organizations in supporting this revision that reflects evidence-based practice. The new label lowers the recommended dosage of one of the two drugs used, extends the timeframe for when a woman can take the pill, and reduces the number of visits a woman must make to her provider.

ARHP supports the FDA’s efforts to make changes that are safe and effective for patients while also demonstrating the importance of increased access to the full spectrum of reproductive health care, including abortion care. Under these new label guidelines, women will now be able to undergo medication abortion with fewer associated costs, side effects, and more convenience.

ARHP encourages states that have enacted laws based on old labeling to revise their laws according to the new prescription guidelines. This will help ensure women have access to this safe and legal medication abortion, regardless of their geographic location in the US.

Looking for medically accurate, up-to-date, evidence-based educational programming for health care providers and materials for patients on all reproductive health topics, including abortion, contraception, HPV, menopause, menstruation, pregnancy, sexuality? Look no further than the Association of Reproductive Health Professionals (ARHP) – the leading source for trusted medical education and information on reproductive and sexual health.